Akebia Therapeutics
Clinical trials sponsored by Akebia Therapeutics, explained in plain language.
-
New drug hopes to slow kidney damage in FSGS patients
Disease control Recruiting nowThis study tests a new drug, praliciguat, for people with a kidney disease called focal segmental glomerulosclerosis (FSGS). About 60 adults will be randomly assigned to take either the drug or a placebo for 24 weeks, followed by 24 weeks where everyone gets the drug. The main go…
Phase: PHASE2 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug AKB-9090 takes first step: safety check in healthy volunteers
Knowledge-focused Recruiting nowThis study is the first time AKB-9090 is being tested in humans. It aims to check the drug's safety and how the body processes it in about 70 healthy adults. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the…
Phase: PHASE1 • Sponsor: Akebia Therapeutics • Aim: Knowledge-focused
Last updated May 26, 2026 07:15 UTC